Physician profile
Angela Yen Moore
NPI 1235142266
$423,264.76
in general payments reported to CMS, 2019-2025
56 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $115K · 2020: $53K · 2021: $46K · 2022: $85K · 2023: $56K · 2024: $51K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Consulting Fee: $26K · Food and Beverage: $17K · Travel and Lodging: $8,206 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,100.00 |
| Consulting Fee | $26,190.00 |
| Food and Beverage | $17,392.93 |
| Travel and Lodging | $8,205.72 |
| Education | $230.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $129,520.97 | 2019-2024 | Klisyri, Seysara |
| Vyne Pharmaceuticals INC. | $70,139.47 | 2020-2021 | |
| Abbvie INC. | $59,235.88 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $46,061.92 | 2023-2024 | Ycanth |
| Incyte Corporation | $35,413.34 | 2020-2025 | Opzelura |
| Ucb, INC. | $10,284.45 | 2019-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $7,861.76 | 2019-2025 | Nemluvio, Aklief |
| Biofrontera INC. | $6,919.86 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Aclaris Therapeutics, INC. | $6,733.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $6,291.19 | 2019-2024 | Sotyktu |
| Janssen Global Services, LLC | $6,139.57 | 2024-2025 | |
| Pfizer INC. | $4,553.49 | 2019-2025 | |
| Leo Pharma As | $4,499.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,039.25 | 2024-2025 | |
| Janssen Biotech, INC. | $3,287.85 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $3,079.29 | 2023 | Idacio |
| Epi Health, LLC | $2,662.85 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $2,610.56 | 2019-2025 | |
| Leo Pharma INC. | $2,507.63 | 2019-2025 | Adbry |
| Mayne Pharma Commercial LLC | $2,150.88 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,666.56 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,317.49 | 2019-2023 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $1,016.69 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $848.28 | 2019-2023 | Olumiant |
| Amgen INC. | $631.78 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $559.03 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $502.05 | 2023-2025 | Nuzyra |
| Glaxosmithkline, LLC. | $358.47 | 2023-2025 | Benlysta |
| Sandoz INC. | $303.74 | 2019-2023 | Hyrimoz |
| Genentech, INC. | $262.44 | 2025 | |
| Celgene Corporation | $230.17 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $207.00 | 2020-2025 | Siliq, Jublia, Altreno |
| Dermira, INC. | $187.68 | 2019-2021 | |
| Janssen Research & Development, LLC | $130.70 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $124.83 | 2020 | |
| Organon LLC | $106.15 | 2025 | Vtama |
| Sebela Pharmaceuticals INC. | $101.29 | 2020-2021 | |
| Springworks Therapeutics, INC. | $100.33 | 2025 | Gomekli |
| Regeneron Healthcare Solutions, INC. | $99.95 | 2022-2025 | Libtayo |
| Journey Medical Corporation | $89.80 | 2022-2024 | |
| Dermavant Sciences, INC. | $85.82 | 2022-2023 | Vtama |
| Allergan, INC. | $76.62 | 2019-2021 | |
| Tempus Ai, INC | $72.50 | 2024 | Merlin Test |
| Encore Dermatology INC. | $47.42 | 2019 | |
| Acrotech Biopharma INC. | $34.38 | 2022 | |
| Elekta, INC. | $32.84 | 2024 | Elekta Medical Linear Accelerator |
| Promius Pharma LLC | $22.78 | 2019 | |
| Dusa Pharmaceuticals, INC. | $20.86 | 2019 | |
| Nabriva Therapeutics, Plc | $19.37 | 2022 | |
| Botanix Sb INC | $14.75 | 2025 | Sofdra |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,787.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.